Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

BMS Preemptively Recalling Coumadin

By Drug Discovery Trends Editor | July 12, 2010

NEW YORK (AP) – Bristol-Myers Squibb Co. said it is recalling eight production lots of its anti-clotting drug Coumadin because the amount of the active ingredient in the drug could change.

The company said the recall is a precaution, and no side effects have been reported. Bristol-Myers Squibb is recalling five production lots of Coumadin hospital unit doses and three lots of physician samples. The recall includes only 1-milligram tablets distributed in the U.S. in blister packs. No bottled medicine or other doses are involved.

The New York company said the amount of isopropanol in the tablets could change over time. Isopropanol, or isopropyl alcohol, is used to keep the drug’s active ingredient in a crystalline state. The changing levels of isopropanol could increase or reduce the amount of the active ingredient in the tablets.

Coumadin, also called warfarin, is a common blood thinner that is used to treat or prevent blood clots after surgery. Bristol-Myers Squibb said the risk of clots could increase if the level of active ingredient decreases, and if there is too much of the ingredient, patients face a greater risk of bleeding.

The tablets have expiration dates between June 2011 and November 2012.

Date: July 12, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE